In this context, nanoMIPs have been developed to target ERα and were tested on two different BC cell lines: MCF‐7 (ERα positive) and MDA‐MB‐231 (ERα negative), which represent different subtypes of BC and thus require different treatment in clinical practice. Here, ESR1 is linked to breast cancer.